淺談藥物廣告與化粧品廣告之法律管制路徑【月旦時論】 試閱
Introduction on the Legal Regulation of the Advertisement for Medicine and for Cosmetic
司法院大法官釋字第414號和第744號解釋，分別涉及了具商業言論性質之藥物廣告與化粧品廣告的事前審查。此外，司法院大法官釋字第577號和第623號解釋亦與商業言論有關。有鑑於商業言論事前審查之議題，可謂頗受各界關注，本文以藥物廣告與化粧品廣告為對象，由上揭司法院大法官相關解釋出發，透過全面且系統性的觀察言論自由之保障、商業言論之限制、事前審查制彼此間的互動狀況後，進一步在現行法規之框架下，析論藥物廣告與化粧品廣告所採取之法律管制路徑，並對其妥適性提出初步的反思。
While the point in J.Y. Interpretation No. 414 is the ex-ante review for advertisements for medicine with characteristic of business speech, the theme in No. 744 is the ex ante review for the advertisements for cosmetic with the same characterisitc. In addition, both the No. 577 and No. 623 are about the business speech. Due to the issue about the ex-ante review for the business speech has more attention of the society, the advertisement for medicine and for cosmetic are the subjects in this article. Beginning from the J.Y. Interpretation above, the legal regulation of the advertisements would be analyzed and a rudimentary reflection on its adequacy under the present legal frame would be held in the end by observing totally and systematically on the interactions between the guarantee of free speech, the limit of business speech and the ex-ante review.
134-147
